Pharmacists on the Multidisciplinary Team: Implementing Best Practices in Chemo-Induced Nausea and Vomiting (CINV) Management

Publication
Article
Pharmacy TimesSeptember 2016 Men's Health
Volume 82
Issue 9

This Continuing Education activity is supported by educational grants from Eisai Inc., Merck Sharp & Dohme Corp., and Tesaro, Inc.

This activity is supported by educational grants from Eisai Inc., Merck Sharp & Dohme Corp., and Tesaro, Inc.

Pharmacists on the Multidisciplinary Team: Implementing Best Practices in Chemo-Induced Nausea and Vomiting (CINV) Management

Faculty

Sally Yowell Barbour, PharmD, BCOP, CPP

Director of Oncology Pharmacy Programs

Duke University Hospital

Durham, North Carolina

Chicago, Illinois

Editorial Support

Jeannette Y. Wick, RPh, MBA, FASCP

Freelance Medical Writer

Arlington, Virginia

Visiting Professor

University of Connecticut School of Pharmacy

Storrs, Connecticut

Educational Objectives

After completing this continuing education program, the participant will be able to:

  • Identify guideline-consistent care that recommends antiemetic regimens for chemo-induced nausea and vomiting (CINV)
  • Explain safety and efficacy profiles for established regimens and new antiemetic strategies for CINV
  • Illustrate strategies for managing challenging situations such as breakthrough symptoms, delayed CINV, managing nausea, and providing antiemetic regimens for multiday chemotherapy
  • Examine a multidisciplinary approach to patient education, communication, and ongoing assessment that is most likely to improve outcomes in CINV

Target audience: Pharmacists, health system pharmacists, specialty pharmacists

Type of activity: Application

Release date: September 8, 2016

Expiration date: September 8, 2017

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-16-120-H01-P. The activity is available for CE credit through September 8, 2017.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.